Detailed Analysis Available Live From HealthLeaders-InterStudy Analyst    What: Phone interview with industry expert specializing in the Medicare         managed care marketplace    Who: Medicare Market Analyst Roy Moore, HealthLeaders-InterStudy    How: Available to speak to media by phone; contact Kelly Morphy to arrange        your interview at 615-369-4818  

The Centers for Medicare & Medicaid Services (CMS) announced on June 15 it had reached agreements with insurers accounting for two-thirds of the private fee-for-service (PFFS) market to cease marketing of the product. The agreement will allow CMS to look responsive after receiving criticism by some in Congress for letting marketing abuses go unchecked.

Problems emerged with the marketing of these products when some seniors complained they were enrolled in a more expensive plan than they intended and discovered their physicians were not part of the plan network. In other cases, insurance brokers were accused of enrolling seniors from assisted- living facilities into these plans without their knowledge.

Most of the major providers agreed to temporarily stop selling the PFFS product, including UnitedHealth Group, Humana, WellCare Health Plans, Coventry Health Care, Universal American Financial Corp., BlueCross BlueShield of Tennessee and Sterling Life Insurance.

Roy Moore is a Medicare industry expert with over four years experience covering healthcare market news. Mr. Moore can provide insight into the effects this agreement will have on the overall PFFS market and the major insurers offering PFFS plans, as well as address questions such as:

    -- What happens next to the PFFS market?     -- Are additional firms likely to enter this market, or do the latest        actions slow down the product growth?     -- Does this affect other elements of Medicare Advantage growth?  

To speak with Mr. Moore, please contact Kelly Morphy at HealthLeaders-InterStudy at 615-369-4818 or

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, is the authoritative source for managed care data, analysis, and news. For more information, please visit

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

PRNewswire -- June 20

SOURCE: HealthLeaders-InterStudy

Uptake of Avastin and New Agents from ImClone/Merck Serono, AstraZeneca, and Bayer/Onyx Will Drive Robust Near-Term Growth in the Non-Small-Cell Lung Cancer Drug Market

View Now